#FinalThoughtsFriday from #ASCO2024 OHG's thought leader John Hennessy, from Valuate Health Consultancy, highlights that the focus on personalized care through next-generation sequencing is more pertinent than ever. Efforts to overcome barriers like patient skepticism and complex testing procedures are vital. John advocates for tests that provide clear and personalized benefits to patients, ensuring treatments are tailored to their unique genetic makeup. By addressing these challenges head-on, the healthcare industry can enhance patient outcomes and foster greater trust within diverse patient populations. #ASCO2024 #OHG #BeTheCaseStudy #OHGThoughtLeader #PersonalizedHealthcare #PatientTrust
Omnicom Health Group’s Post
More Relevant Posts
-
Unlock the future of healthcare with #PGXtesting from Gold Coast Diagnostics. Our advanced pharmacogenomic testing services are transforming patient care in hospitals and behavioral health facilities. By analyzing individual genetic profiles, we empower healthcare providers to personalize treatment plans, minimizing adverse reactions and maximizing therapeutic efficacy. #PrecisionMedicine #HealthcareInnovation With our comprehensive #PGXtesting solutions, healthcare professionals can confidently select medications aligned with each patient's unique genetic makeup. Say farewell to the uncertainty of trial-and-error prescribing and embrace precision medicine that enhances outcomes and patient satisfaction. #PersonalizedMedicine Join us in revolutionizing healthcare delivery. Partner with Gold Coast Diagnostics and unlock the full potential of personalized medicine through #PGXtesting. #HealthcareTransformation #MedicalAdvancements
To view or add a comment, sign in
-
Discover the Power of Personalized Health with Vitruvion At Vitruvion, we're dedicated to revolutionizing health and wellness through the power of genomics. Whether you’re a seasoned practitioner or just beginning to explore the potential of personalized health strategies, we invite you to discover how our cutting-edge genomic and biomarker tools can enhance your practice and client outcomes. Why Choose Vitruvion? Advanced Genomic Insights: Harness detailed genetic data to tailor health interventions that truly match your clients' individual needs. Improve Health Outcomes: Utilize our tools to develop personalized strategies that lead to more effective results in wellness and disease prevention. Empower Your Practice: Stand out in your field with the ability to offer scientifically backed, personalized health plans. Interested in learning more? Visit our website or contact us today to explore how Vitruvion can help you lead the way in personalized healthcare. #PersonalizedHealth #Genomics #Vitruvion
To view or add a comment, sign in
-
Using real-world data (RWD) and real-world evidence (RWE) to improve the quality of patient care is about asking questions, says Nicholas Robert, MD. Questions about treatment patterns and outcomes in the real world, biomarker testing, and social determinants of health (SDOH) can help evaluate whether patients are receiving appropriate care. #RWD #RWE #SDOH #Biomarkers
3 Keys to RWD/RWE - Nicholas Robert, MD - Ontada
To view or add a comment, sign in
-
Genetic testing is growing at an unprecedented rate as utilization in November 2022 saw a 15% increase from November 2021, and health plan spending up 11% during the same period. As biomarker legislation requiring health plans to include coverage for biomarker tests gains traction throughout the U.S., health plans will face the increased challenge of determining which tests are clinically valid and offer the greatest patient benefits. In a recent article with Health Payer Specialist, Avalon Executive VP of Product, Jason Bush, Ph.D., MBA, explores how health plans can modernize genetic test management programs to meet the current need: https://lnkd.in/exbMqjAM #AvalonHCS #GeneticTesting #RightTest #ValueDrivenCare
To view or add a comment, sign in
-
Today is #rarediseaseday2024 and in this article Sprout Health Solutions' Beverly Romero discusses how we can overcome challenges in rare disease patient research 👉 https://lnkd.in/eSDDd2FQ
🌟 Overcoming Challenges in Rare Disease Patient Research 🌍 The small populations linked with rare and ultra-rare diseases pose significant challenges for pharma and biotech companies. In the February issue of PME, Sprout Senior Principal Beverly Romero shares five strategies to navigate these complexities in qualitative patient research. 📊 Based on Sprout Health Solutions extensive experience, these strategies include innovative approaches to recruitment and a patient-focused methodology for data collection. 🤝📝 📚 Read more! 👉 https://lnkd.in/eSDDd2FQ #RareDisease #PatientEngagement #PharmaInsights #HealthTech #RareDiseaseAwareness #PatientAdvocacy #HealthcareResearch #ClinicalTrials #PatientVoice #QualitativeResearch #PatientResearch #PatientData #PatientRecruitment
To view or add a comment, sign in
-
Finding the right patients for a new drug is like finding the perfect puzzle piece - crucial for success, especially in complex cases like Sickle Cell Disease (SCD). Traditional methods often struggle, hampered by both the intricate patient journey and limited data. But what if you could unlock the missing piece? This case study dives into how we helped a client identify the ideal healthcare professionals (HCPs) for their SCD treatment. Through innovative strategies, we achieved remarkable outcomes: 🔺8% rise in identified potential patients. 🔺Recognition of 68% of top-tier hospitals and their HCPs Click here to delve deeper into this success story.👇 https://bit.ly/3vsNodp #insight #sicklecell #raredisease #healthcare
To view or add a comment, sign in
-
Normal ranges in blood tests almost aren't worth the paper they're printed on. All they really give you is a measure of how sick you are based on population averages of a population that is becoming increasingly more dysfunctional from a health perspective. That's why at FDX we use optimal reference ranges of the 130+ biomarkers we can measure. It means we have a super-accurate picture of what's happening when it comes to clients - but also allows us to look at all the interactions between biomarkers to create targeted protocols that work. If you want to optimise your clients' health and grow your clinic, there's only one choice: FunctionalDX. See our website for more https://buff.ly/2G3fcbF
To view or add a comment, sign in
-
🌟 Overcoming Challenges in Rare Disease Patient Research 🌍 The small populations linked with rare and ultra-rare diseases pose significant challenges for pharma and biotech companies. In the February issue of PME, Sprout Senior Principal Beverly Romero shares five strategies to navigate these complexities in qualitative patient research. 📊 Based on Sprout Health Solutions extensive experience, these strategies include innovative approaches to recruitment and a patient-focused methodology for data collection. 🤝📝 📚 Read more! 👉 https://lnkd.in/eSDDd2FQ #RareDisease #PatientEngagement #PharmaInsights #HealthTech #RareDiseaseAwareness #PatientAdvocacy #HealthcareResearch #ClinicalTrials #PatientVoice #QualitativeResearch #PatientResearch #PatientData #PatientRecruitment
To view or add a comment, sign in
-
Senior Scientific Director at Ontada | Genetic Epidemiologist and Data Scientist in Cancer 'Omics Data | Patient Empowerment and Engagement through Health Information | Race and Ancestry in Biomedical Science
"We owe it to our patients to get it right." - Lisa McShane Additional insight in her answer was how much patients hang by every test. *This* is why we need to open up patient crowdsourcing of science through patient ownership of their data and empowered engagement with research. Once we accomplish this, real world evidence (RWE) generation will stand to blow the clinical trial/ experimental approach to medical developments out of the water. The clinical trial is just a historical artifact that we are having difficulty shedding, and which does NOT scale in a world of big data and AI. Small scale, top down "experiments" is not how we get at complex systems causality OR understanding, and should much less be considered the gold standard for evidence generation. RWE through empowered patients who own their data has to be looked at as the completely new and the up and coming approach, and RWD needs to stop ✋️ trying to be hammed into clinical trial derived "fit for purpose" little boxes. Let's switch the "fit for purpose" hyperfocus which is myopic and a relic from past frameworks, to patient ownership through web 3 and blockchain as the way to accelerate translation of new technologies and science to patient benefit, as the way to accelerate their use within the clinical encounter. Our antiquated and bloated systems in place will not do this, but I have confidence that patients WILL.
Watch #HRD project partner Lisa McShane from the The National Institutes of Health speaking to the importance of the HRD biomarker for patients. #HRDFriends
To view or add a comment, sign in
-
Exciting news! Our team is thrilled to announce the release of our 2nd Annual State of Health Care Report! This report highlights the strategic role of health benefits in attracting and retaining top talent, controlling costs, and enhancing benefit communication. Key findings reveal the pressing need for benefit customization to meet workforce desires. We also discovered emerging health benefit trends, including rises in weight loss medication coverage, the use of self-insurance models, gene therapy benefits, and infertility treatment support. Don't miss out on the full insights! Dive into the report now. #CBIZ #StateOfHealthcare
To view or add a comment, sign in
48,633 followers